WillItSurvive
No grouping · subsidiary of BioVie Inc. · United States

Option Therapeutics Inc.

Pre-revenue BioVie spinout developing a liquid terlipressin drug for liver disease ascites.

Little protection left
Assessed 29 July 2026 · Evidence as of 29 July 2026
Not much stands between this business and its pressures.
On the recordSince 29 July 2026 · Checkable from H2 2026 · Every call on the record Checkpoint: IPO pricing/closing confirmation and any disclosed Phase 3 funding or FDA End-of-Phase-2 alignment
The call

Option Therapeutics is a single-asset, pre-revenue carve-out leaning on Fast Track and Orphan status while its controlling parent's stock sits near zero and its only rival drug is already approved.

Option Therapeutics is a brand-new company spun out in 2025 to develop BIV201, an experimental drug for a serious liver condition called hepatorenal syndrome. The company faces an uphill battle because Mallinckrodt already sells Terlivaz, a similar drug approved by the FDA in 2022 that doctors are using in real patients right now, making it harder for a new unproven medicine to stand out. The company raised only $20 million but will need roughly $50 million to $150 million or more to run the testing required to get FDA approval, and its parent company BioVie is financially struggling, which raises questions about whether either company can survive long enough to finish the job.

Why
01
AI pressure: None apparent. No AI-driven diagnostic or drug-discovery rival named in filings; clinical trials, not algorithms, decide this company's fate. Could AI do the core job? Unlikely.
02
Bigger players: Mallinckrodt Pharmaceuticals (Terlivaz, same molecule terlipressin, FDA-approved 2022). Mallinckrodt already sells an approved terlipressin drug and is generating real-world data that could expand toward Option's target use. Could a giant copy it? Probably.
03
What protects it. FDA Fast Track and Orphan Drug designations plus a patent-pending continuous-infusion formulation, both unproven until Phase 3 data lands.
What would change this call
Whether the OPTN IPO actually prices and begins trading on NYSE American. Shows whether the company secures even its minimal $20M funding base.
Whether BioVie's market cap or going-concern disclosures worsen further in 2026 filings. Shows whether the controlling parent's distress threatens Option Therapeutics' funding and control.
Whether Option Therapeutics announces a funded Phase 3 trial or FDA SPA/End-of-Phase-2 alignment. Shows whether BIV201 gains a credible regulatory path toward approval.
Key numbers
  • IPO downsized to about $20M gross proceeds (2026-03-16)
  • Parent BioVie market cap about $9.9M, down 85% YoY (2026-07-29)
  • Company reports only 3 employees at filing (2026-03-15)
Named risks
  • Majority owner BioVie is financially distressed, market cap ~$9.9M and down 85% YoY as of July 29, 2026. Severity: high
  • Phase 2 trial terminated early and underpowered, no definitive efficacy shown as of 2025. Severity: high
  • IPO raise of ~$20M is far below typical $50-150M+ Phase 3 trial cost for liver disease drugs. Severity: high
  • OPTN IPO pricing and completion date remain unconfirmed as of July 29, 2026. Severity: medium
  • Only 3 employees, reliant on BioVie's shared infrastructure with no independent operational scale. Severity: medium
Rivals, as read in July 2026
RivalDirectionEvidence
Mallinckrodt Pharmaceuticals (Terlivaz)gaining onFDA-approved since Sept 14, 2022; active real-world data presentations through 2025-2026
Keenova TherapeuticscontestingPresenting real-world terlipressin utilization data at 2026 conferences
Questions people ask
Is Option Therapeutics profitable?
No. Option Therapeutics is pre-revenue with $0 in sales and reported a net loss of about $1.28M EBIT in its S-1/S-1A financials as of March 16, 2026. It has no approved product and only 3 employees, making profitability years away at best.
Who owns Option Therapeutics?
Option Therapeutics is a carve-out of BioVie Inc. (NASDAQ: BIVI), which held 100% of shares pre-IPO. Post-IPO, BioVie is expected to retain at least 60% ownership and voting control, per a March 17, 2026 report, keeping the parent firmly in charge.
Did the Option Therapeutics IPO (OPTN) actually happen?
As of July 29, 2026, the OPTN IPO had not been confirmed as priced or trading. The S-1 was filed January 26, 2026 targeting $25.3M, downsized to about $20M via S-1/A on March 16, 2026, but tracker sites still showed blank pricing pages.
How is BioVie's financial health, the parent of Option Therapeutics?
Weak. BioVie (BIVI) had a market cap of roughly $9.9M as of July 29, 2026, with its share price down about 85% year over year, signaling a financially distressed majority owner underwriting the Option Therapeutics spin-out.
Could AI replace what Option Therapeutics does?
No. Its core assets are FDA Fast Track and Orphan Drug designations plus issued patents (US 11,364,277, EP3347032) covering BIV201, a terlipressin formulation for ascites. These regulatory and legal protections require clinical trials and agency approval, which AI cannot substitute for or bypass.
Who is Option Therapeutics' biggest competitor?
Mallinckrodt Pharmaceuticals, via its FDA-approved Terlivaz (terlipressin acetate), approved September 14, 2022 for hepatorenal syndrome with acute kidney injury. Terlivaz uses the same underlying molecule as Option's BIV201 and has been generating active real-world data through 2025-2026.
Timeline
  • 2026-07-29BioVie market cap ~$9.9M, down ~85% YoY; OPTN IPO pricing still unconfirmed
  • 2026-05-25Mallinckrodt reported presenting ongoing real-world Terlivaz data through 2026
  • 2026-03-17Report confirms BioVie to retain 60%+ ownership of Option Therapeutics post-IPO
  • 2026-03-16S-1/A downsizes OPTN IPO to 1.8M shares, targeting ~$20M gross
  • 2026-03-15Renaissance Capital profile discloses 3 employees, $0 revenue, patent estate
  • 2026-01-26Option Therapeutics files S-1 for NYSE American listing (OPTN), targeting $25.3M
  • 2025Phase 2 results published showing non-statistical trends, no definitive efficacy
  • 2024-05-07Phase 2 trial NCT04112199 confirmed terminated early, underpowered
  • 2023-11-13BioVie reports positive Phase 2b safety data, plans Phase 3 start for Q2 2024
  • 2023-03-12BioVie pauses patient enrollment in ascites Phase 2b trial
Revision history
29 July 2026
First assessed. Little protection left. The text above is fixed as of this date and is not edited afterwards.
In the same band
Optimum CommunicationsWarner Bros. DiscoveryInflection AI
More companies little protection left →
Sources